American Association for Cancer Research
10780432ccr150428-sup-145782_1_supp_2943753_nmyzxw.pdf (102.34 kB)

Supplementary Figure S2 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

Download (102.34 kB)
journal contribution
posted on 2023-03-31, 18:29 authored by Christine E. Brown, Behnam Badie, Michael E. Barish, Lihong Weng, Julie R. Ostberg, Wen-Chung Chang, Araceli Naranjo, Renate Starr, Jamie Wagner, Christine Wright, Yubo Zhai, James R. Bading, Julie A. Ressler, Jana Portnow, Massimo D'Apuzzo, Stephen J. Forman, Michael C. Jensen

Supplementary Figure S2. Consort flow diagram.



Purpose: A first-in-human pilot safety and feasibility trial evaluating chimeric antigen receptor (CAR)–engineered, autologous primary human CD8+ cytotoxic T lymphocytes (CTL) targeting IL13Rα2 for the treatment of recurrent glioblastoma (GBM).Experimental Design: Three patients with recurrent GBM were treated with IL13(E13Y)-zetakine CD8+ CTL targeting IL13Rα2. Patients received up to 12 local infusions at a maximum dose of 108 CAR-engineered T cells via a catheter/reservoir system.Results: We demonstrate the feasibility of manufacturing sufficient numbers of autologous CTL clones expressing an IL13(E13Y)-zetakine CAR for redirected HLA-independent IL13Rα2-specific effector function for a cohort of patients diagnosed with GBM. Intracranial delivery of the IL13-zetakine+ CTL clones into the resection cavity of 3 patients with recurrent disease was well-tolerated, with manageable temporary brain inflammation. Following infusion of IL13-zetakine+ CTLs, evidence for transient anti-glioma responses was observed in 2 of the patients. Analysis of tumor tissue from 1 patient before and after T-cell therapy suggested reduced overall IL13Rα2 expression within the tumor following treatment. MRI analysis of another patient indicated an increase in tumor necrotic volume at the site of IL13-zetakine+ T-cell administration.Conclusions: These findings provide promising first-in-human clinical experience for intracranial administration of IL13Rα2-specific CAR T cells for the treatment of GBM, establishing a foundation on which future refinements of adoptive CAR T-cell therapies can be applied. Clin Cancer Res; 21(18); 4062–72. ©2015 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager